The ESMO Asia Congress 2023 highlighted two significant studies on EGFR mutations in non-small cell lung cancer (NSCLC). The MARIPOSA-2 trial showed amivantamab with chemotherapy improved progression-free survival in Asian patients with EGFR-mutated NSCLC by 46% over chemotherapy alone. The FLAURA2 trial showed that adding platinum-based chemotherapy to osimertinib doesn’t impact resistance mechanisms, indicating no limitations on future treatments. Dr. Antonio Passaro emphasized the potential transformation of EGFR-mutated NSCLC treatment with these findings, despite higher toxicity and ongoing challenges in comprehensive molecular analysis and addressing global treatment disparities.

Reference: Additional data confirm the promise of combination therapies for EGFR-mutated NSCLC. ESMO Daily Reporter. Published December 3, 2023. Accessed December 7, 2023. https://dailyreporter.esmo.org/esmo-asia-congress-2023/latest-news/additional-data-confirm-the-promise-of-combination-therapies-for-egfr-mutated-nsclc